Last reviewed · How we verify
NCT04666805
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast
trial testing Tamoxifen in Breast Cancer in 1,354 participants. Status unknown.
1 January 2021
Quick facts
| Lead sponsor | First Hospital of China Medical University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,354 |
| Start date | 1 July 2020 |
| Primary completion | 1 January 2021 |
| Estimated completion | 15 January 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Tamoxifen
- Toremifene (TOREMIFENE) — full drug profile →
- Anastrozole (anastrozole) — full drug profile →
- Letrozole — full drug profile →
- Exemestane (exemestane) — full drug profile →
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
First Hospital of China Medical University
Who can join
Adults 18 to 85, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will investigate the relationship between the endocrine therapy and the survival of patients with hormone receptor positive intraductal carcinoma of the breast, and the optimal duration of medication. This study will also analyze the risk factors of recurrence and metastasis of hormone receptor positive intraductal carcinoma of the breast and establish a prognosis model to further clarify the specific reasons for recurrence and metastasis, adverse reactions, and drug withdrawal in patients with hormone receptor positive intraductal carcinoma of the breast after endocrine therapy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Endocrine therapy of short duration prevents local and contralateral recurrence of ductal carcinoma in situ of the breast: A multicenter retrospective cohort study in China.
Wang Z, Jin Z, Zhang H, Xu G, et al · · 2024 · PMID 38951018 · DOI 10.1097/cm9.0000000000003157
Verify or expand the search:
- PubMed search for NCT04666805
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tamoxifen
Trials testing the same drug.
- NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
- NCT06434064 — Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advan · Phase 2 · recruiting
- NCT06942039 — Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation · EARLY_PHASE1 · recruiting
- NCT06979596 — A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) · Phase 2 · recruiting
- NCT06195306 — Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction · Phase 2 · recruiting
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other First Hospital of China Medical University trials
Trials by the same sponsor.
- NCT07350486 — LLM-CoManage: Large Language Model-Enabled Co-Management of Hypertension, Diabetes, and Dyslipidemia · NA · not yet recruiting
- NCT07534865 — Hyperthermia Combined With Hydrogen Peroxide Microneedle Patch for Viral Warts · NA · recruiting
- NCT07476898 — Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window · Phase 3 · not yet recruiting
- NCT07319065 — Left Ventricular Myocardial Work for Predicting Response to CRT · not yet recruiting
- NCT07286812 — Digital Technology Combined With Blood Marker Screening and Diagnosis for Community Populations Based on Classification · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04666805 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Hospital of China Medical University
- Last refreshed: 14 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04666805.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing